rs193922587
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 1P and 5B. BP5BS2PM2_Supporting
This summary comes from the ClinGen Evidence Repository: The c.1663C>T variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of leucine to phenylalanine at codon 555(p.(Leu555Phe)) of NM_000545.8. This variant has an allele frequency of 0.00001797 in Non-Finnish Europeans, below the MDEP threshold of 0.00002, and no copies in other subpopulations, in gnomAD v2.1.1 (PM2_Supporting). Additionally, this variant was identified in the homozygous state in a 56 year old normoglycemic individual (BS2; PMID:22341299). Lastly, this variant was identified in a patient with an alternate molecular basis for disease (BP5; PMID:22341299). This variant was identified in one individual with non-autoimmune and non-absolute/near-absolute insulin-deficient diabetes; however, PS4_Moderate cannot be applied because this number is below the ClinGen MDEP threshold (internal lab contributors). This variant has a REVEL score of 0.5809, which is between the ClinGen MDEP thresholds, predicting neither a damaging nor benign impact on HNF1A function. In summary, c.1663C>T meets the criteria to be classified as likely benign for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 6/4/2021): PM2_Supporting, BS2, BP5. LINK:https://erepo.genome.network/evrepo/ui/classification/CA214281/MONDO:0015967/017
Frequency
Consequence
NM_000545.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
HNF1A | NM_000545.8 | c.1663C>T | p.Leu555Phe | missense_variant | 9/10 | ENST00000257555.11 | NP_000536.6 | |
HNF1A | NM_001306179.2 | c.1684C>T | p.Leu562Phe | missense_variant | 9/10 | NP_001293108.2 | ||
HNF1A | NM_001406915.1 | c.1471C>T | p.Leu491Phe | missense_variant | 8/9 | NP_001393844.1 | ||
HNF1A | XM_024449168.2 | c.1756C>T | p.Leu586Phe | missense_variant | 8/9 | XP_024304936.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
HNF1A | ENST00000257555.11 | c.1663C>T | p.Leu555Phe | missense_variant | 9/10 | 1 | NM_000545.8 | ENSP00000257555.5 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 exomes AF: 0.00000806 AC: 2AN: 248172Hom.: 0 AF XY: 0.00000743 AC XY: 1AN XY: 134650
GnomAD4 exome AF: 0.0000212 AC: 31AN: 1461242Hom.: 0 Cov.: 69 AF XY: 0.0000179 AC XY: 13AN XY: 726932
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Maturity-onset diabetes of the young type 3 Pathogenic:1Uncertain:1
Likely pathogenic, criteria provided, single submitter | clinical testing;curation | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 18, 2011 | - - |
Uncertain significance, criteria provided, single submitter | curation | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Jan 22, 2020 | The p.Leu555Phe variant in HNF1A has been reported in 1 individual with maturity-onset diabetes of the young type 3 (PMID: 18003757) and has been identified in 0.001797% (2/111302) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs193922587). This variant has also been reported in ClinVar (VariationID: 36808) as likely pathogenic by Integrated Genetics. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. One affected individual with this variant have an alternative molecular basis for maturity-onset diabetes of the young, suggesting that this variant may not be pathogenic (PMID: 22341299). In summary, the clinical significance of the p.Leu555Phe variant is uncertain. ACMG/AMP Criteria applied: PM2, BP5 (Richards 2015). - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 14, 2021 | This sequence change replaces leucine with phenylalanine at codon 555 of the HNF1A protein (p.Leu555Phe). The leucine residue is weakly conserved and there is a small physicochemical difference between leucine and phenylalanine. This variant is present in population databases (rs193922587, ExAC 0.002%). This missense change has been observed in individual(s) with maturity-onset diabetes of the young type 3 (PMID: 18003757). This missense change has been observed to be homozygous or hemizygous in an individual who did not have the expected clinical features for that genetic result (PMID: 22341299). ClinVar contains an entry for this variant (Variation ID: 36808). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Monogenic diabetes Benign:1
Likely benign, reviewed by expert panel | curation | ClinGen Monogenic Diabetes Variant Curation Expert Panel | Dec 31, 2021 | The c.1663C>T variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of leucine to phenylalanine at codon 555(p.(Leu555Phe)) of NM_000545.8. This variant has an allele frequency of 0.00001797 in Non- Finnish Europeans, below the MDEP threshold of 0.00002, and no copies in other subpopulations, in gnomAD v2.1.1 (PM2_Supporting). Additionally, this variant was identified in the homozygous state in a 56 year old normoglycemic individual (BS2; PMID: 22341299). Lastly, this variant was identified in a patient with an alternate molecular basis for disease (BP5; PMID: 22341299). This variant was identified in one individual with non-autoimmune and non-absolute/near-absolute insulin-deficient diabetes; however, PS4_Moderate cannot be applied because this number is below the ClinGen MDEP threshold (internal lab contributors). This variant has a REVEL score of 0.5809, which is between the ClinGen MDEP thresholds, predicting neither a damaging nor benign impact on HNF1A function. In summary, c.1663C>T meets the criteria to be classified as likely benign for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 6/4/2021): PM2_Supporting, BS2, BP5. - |
HNF1A-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Apr 29, 2024 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Maturity onset diabetes mellitus in young Other:1
Uncertain risk allele, criteria provided, single submitter | research | Clinical Genomics, Uppaluri K&H Personalized Medicine Clinic | - | Mutations in HNF1A gene can predispose to MODY3. It is associated with both micro and macrovascular complications of diabetes, especially cardiovascular complications. Associated with glucosuria. May respond well to sulfonylureas. However, more evidence is required to confer the association of this particular variant rs193922587 with MODY3. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at